Predicting steroid response in severe autoimmune hepatitis
Part of Digestive system, Immune system & allergy clinical trials.
This study is testing a new way to predict how well steroid treatment will work for people with severe autoimmune hepatitis, a condition where the immune system attacks the liver. If you qualify, the findings may help doctors personalize your care and improve outcomes.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years or older.
- You have a severe, sudden liver inflammation that is likely autoimmune (your immune system is attacking your liver).
- Your blood test shows slow clotting (INR of 1.5 or higher).
- You do not have a history of chronic liver disease or other causes of sudden liver failure.
- You have not taken corticosteroids in the past month and are not pregnant or breastfeeding.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study collects information and blood samples from people with autoimmune hepatitis and other liver conditions to better understand these diseases. Taking part may help with research, though it is not a treatment trial.
This study looks at what factors affect how well the liver responds to treatment in people with autoimmune hepatitis. It may help doctors understand why some people respond better than others and could lead to more personalized care.
This study looks at whether a specific blood marker can predict which patients with liver inflammation will need long-term steroid treatment. It may help doctors decide the best treatment for you if you have unexplained liver injury.
This trial checks if the absence of certain antibodies in autoimmune hepatitis (AIH) is linked to more severe disease. It may help doctors better understand and treat AIH.
This study compares a blood-filtering treatment called therapeutic plasma exchange with standard medicines for people with severe autoimmune hepatitis. It aims to see if plasma exchange can improve outcomes when a liver transplant is not available soon.
This study compares two medicines, azathioprine and mycophenolate mofetil, to see which works better for treating autoimmune hepatitis. If you haven't been treated before, this trial could help find a more effective way to manage your condition.
Hear when a new Risk Factors trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.